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Statement of translational relevance 
The clinical management of small cell lung cancer (SCLC) has remained largely unchanged for over 30 
years due in part to the lack of model systems that predict clinical outcomes.  SCLC prognosis 
remains dismal.  Our recent introduction of SCLC circulating tumor cell derived explant models (CDX) 
that can be generated from a simple patient blood draw before treatment and again after treatment 
upon disease relapse offers research opportunities to test new therapies and explore predictive 
biomarkers.  Here we report promising data in multiple CDX models that supports a combination of 
PARP and WEE1 inhibitors in SCLC that is superior in efficacy to standard of care chemotherapy.   We 
also identify a 'super-responder' CDX model that provides molecular insights into strategies for 
patient selection for this drug combination. 
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Abstract 
Purpose: Introduced in 1987, platinum-based chemotherapy remains standard of care for small cell 
lung cancer, a most aggressive, recalcitrant tumor.  Prominent barriers to progress are paucity of 
tumor tissue to identify drug targets and patient relevant models to interrogate novel therapies. 
Following our development of circulating tumour cell patient-derived explants (CDX) as models that 
faithfully mirror patient disease, here we exploit CDX to examine new therapeutic options for small 
cell lung cancer.  
Experimental Design:  We investigated the efficacy of the PARP inhibitor olaparib alone or in 
combination with the Wee1 kinase inhibitor AZD1775 in ten phenotypically distinct SCLC CDX in vivo 
and/or ex vivo. These CDX represent chemosensitive and chemorefractory disease including the first 
reported paired CDX generated longitudinally before treatment and upon disease progression.  
Results: There was a heterogeneous depth and duration of response to olaparib/AZD1775 which 
diminished when tested at disease progression.  However, efficacy of this combination consistently 
exceeded that of cisplatin/etoposide with cures in one CDX model.  Genomic and protein analyses 
revealed defects in homologous recombination repair and oncogenes that induce replication stress 
(such as MYC family members), predisposed CDX to combined olaparib/AZD1775 sensitivity though 
universal predictors of response were not noted. 
Conclusions: These preclinical data provide a strong rationale to trial this combination in the clinic 
informed by prevalent, readily accessed circulating tumor cell based biomarkers. New therapies will 
be evaluated in SCLC patients after first line chemotherapy and our data suggest that the 
combination of olaparib/AZD1775 should be used as early as possible and prior to disease relapse.  
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Introduction  
Small cell lung cancer (SCLC) is an aggressive and recalcitrant neuroendocrine tumor which 
metastasizes early (1). The 5 year survival rate for SCLC has been less than 5% for over 30 years, 
despite multiple phase I clinical trials with a variety of molecularly targeted agents. While platinum-
based therapies yield objective response rates in the majority of patients, this benefit is usually 
transient with relapse frequently occurring in less than one year from initial diagnosis (2). Recent 
large scale genome sequencing efforts have failed to identify recurrent actionable mutations in SCLC 
and the failure to improve survival rates has largely been attributed to the fact that few patients 
undergo surgery, and thus the amount of tissue available for research is limited and tumor biopsies 
at disease relapse after chemotherapy are rarely obtained (1).   
We recently reported the generation of CTC-derived explant (CDX) models in which circulating tumor 
cells from extensive stage SCLC patients are grown subcutaneously in immunocompromised mice 
(3). CDX models provide additional material to examine the biology of SCLC and serve as a robust 
and relevant preclinical pharmacology platform to examine the efficacy of new potential therapies.  
Importantly, the in vivo response to standard of care chemotherapy in CDX models closely resembles 
that of the corresponding donor patient, suggesting that preclinical results for experimental 
therapies may be more robust for translation to the clinic than conventional cell line-based 
xenografts. 
Proteomic profiling in lung cancer cell lines revealed elevated levels of poly (ADP-ribose) polymerase 
(PARP) specifically in SCLC (4). PARP is recruited to DNA single strand breaks (SSBs) where it 
PARylates multiple substrates including histones to facilitate the relaxation of chromatin, as well as 
itself. The auto-modification of PARP is required for its dissociation from DNA and subsequent 
repair. The mechanism of action for PARP inhibitors with single agent activity has been proposed to 
involve the trapping of PARP onto the DNA single-strand breaks preventing their repair and 
generating a potential block for cellular DNA replication (5,6).  An important consequence of this and 
the proposed basis of monotherapy activity is the generation of DNA double strand breaks (DSBs) 
that would normally be repaired by the Homologous Recombination Repair (HRR) pathway. In 
cancers with HRR deficiency, PARP trapping will result in significant genomic instability until it is no 
longer sustainable and tumor cell death results (7). Although deficiencies in the breast and ovarian 
cancer associated genes BRCA1 and BRCA2 are the most investigated examples of defective 
components of HRR that lead to increased PARP inhibitor activity, mutations in other HRR pathways 
genes, including ATM, ATR, and PALB2, can also convey sensitivity to PARP inhibitors (8). 
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Wee1 is a kinase that regulates both S-phase and G2/M progression by phosphorylating and 
inhibiting the cell cycle dependent kinases CDK2 and CDK1 respectively. Wee1 control of CDK2 
activity in S-phase is an important component of the replication stress response, whereas the 
control of CDK1 and the G2/M checkpoint is critical for ensuring proper DNA repair before initiating 
cell division (9). Initially, it was hypothesized that cells deficient for the tumor suppressor p53 were 
hyper-reliant on Wee1 function and the G2/M checkpoint, and that efficacy of the Wee1 inhibitors 
could be linked to TP53 status (10). Subsequent experiments revealed that this correlation was not 
universally true, although Wee1 inhibitor activity is still likely linked to G1/S checkpoint deficiencies 
in one form or another (11). Recent reports suggest that cells overexpressing potent oncogenes, 
such as MYC or CCNE1, that induce replication stress are also more sensitive to Wee1 inhibition, but 
again does not appear to be a universal pre-requisite for response (9). 
Given the potential for PARP inhibitors to induce S-phase damage and a subsequent dependency on 
Wee1 S-phase and G2/M checkpoint activities, coupled with the high mutagenic burden and 
proliferative rate of SCLC, we examined the efficacy of the PARP inhibitor olaparib and the Wee1 
inhibitor AZD1775 in our SCLC CDX models. The most important advantage of the CDX approach is 
the ability to assess biology and therapy responses not only in patient derived models generated at 
baseline prior to any treatment, but also in CDX derived from the same patient at disease 
progression after treatment. Here, we examine the novel combination of olaparib and AZD1775 for 
the first time in ‘paired’ CDX, providing a clinically relevant test-bed for the introduction of new 
therapeutic options following first line chemotherapy.    
Our studies reveal that SCLC CDX tumors exhibit a range of sensitivities to drugs targeting PARP and 
Wee1 as single agents, but with clear indications of enhanced efficacy when given in combination. 
Moreover, these studies have revealed the presence of previously unappreciated DNA damage 
response deficiencies in a subset of SCLC tumors. These results therefore provide a strong rationale 
for the clinical development of AZD1775 in combination with olaparib or other DNA damaging 
agents, as well as candidate biomarkers to explore in tandem towards a precision medicine approach 
for this disease. 
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Materials and methods 
Study design 
The primary goal of this study was to assess the efficacy of olaparib and AZD1775 montherapies, as 
well as the combination, in mouse models of SCLC.  Sample sizes (n = 7-11 mice per cohort) was 
determined to detect statistically a two-fold difference in tumor response between the various 
treatments. Once tumours reached enrollment size, animals were allocated to different cohorts via 
stratified randomization in which attempts were made to evenly distribute initial tumour volume 
sizes.  Data collection was stopped at ethical endpoints, including deterioration in health or when 
tumors reached ≥ four times the initial tumor volume at enrollment.  If animals became ill within 3 
days of enrollment, they were excluded from the experiment, regardless of which treatment they 
received.  No other data were excluded.   
CDX establishment 
CDX models were generated as previously described (3). Briefly, 10ml of peripheral blood was 
collected from SCLC patients into EDTA tubes in accordance with the ethically approved CHEMORES 
protocol (07/H1014/96), processed via RosetteSep CTC Enrichment Cocktail (15167, Stemcell 
Technologies), and resuspended in 100µl of a 1:1 solution of HITES medium and Matrigel (354234, 
BD Biosciences).  Cells were then subcutaneously implanted into flanks of 8-16 week old female 
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice (Charles River). All procedures were carried out in 
accordance with Home Office Regulations (UK) and the UK Coordinating Committee on Cancer 
Research guidelines and by approved protocols (Home Office Project license nos. 40-3306/70-8252 
and Cancer Research UK Manchester Institute Animal Welfare and Ethical Review Advisory Board).  
In a parallel patient blood sample, CTC burden was quantified via CellSearch according to 
manufacturer’s instructions. 
In vivo pharmacology studies 
Therapeutic studies were carried out essentially as previously described (3). 100,000 viable CDX cells 
in 100µl 1:1 RPMI:matrigel were injected subcutaneously into the right flank of procedure/treatment 
naïve, 8-10 week old (20-25g) female C.B-17/lcrHsd-PrkdcscidLystbg-J mice (Envigo). When tumors 
reached 150–250 mm3, they were allocated via stratified randomisation into cohorts to be treated 
each morning with vehicle(s), olaparib (50 mg kg-1 unless indicated otherwise), AZD1775 (120 mg kg-
1), the combination, or topotecan using tolerated dosing regimens previously shown to optimally 
achieve target inhibition. Olaparib (AstraZeneca) was formulated at 10 mg ml-1 in 10% DMSO/30% 
KLEPTOSE® HPCD and AZD1775 (AstraZeneca) was formulated at 12 mg ml-1 in 0.5% 
methylcellulose. Compounds were orally dosed at 5 ml kg-1 daily (olaparib) or 10 ml kg-1 on a 5-on, 2-
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off (AZD1775) schedule for 21 days. On days when both drugs were administered, olaparib was 
administered 1 hour after AZD1775. Topotecan (The Christie NHS Foundation Trust) was 
administered at 3 mg kg-1 daily for three days via intraperitoneal injection.  Cisplatin and etoposide 
(The Christie NHS Foundation Trust) were administered as previously described (3), and these 
studies were performed separately from studies on olaparib and AZD1775.  Mice were observed for 
a period of time post dose to ensure no adverse effects were seen. Tumors were measured twice a 
week by caliper until they reached four times initial tumor volume (4×ITV), as determined by the 
formula V=(L x W2)/2, or until animal health deteriorated. For pharmacokinetic and 
pharmacodynamic studies, mice were sacrificed two or 24 hours after a single dose of indicated 
drugs were administered and relevant tissues were collected.  Statistical assessment of tumor 
response was performed as described (12).  Tumor growth delay (TGD) measures the normalized 
time to quadrupling of initial tumor growth, and therefore a higher TGD value is indicative of more 
robust tumor growth inhibition. 
Pharmacokinetic analysis 
25µl plasma was prepared using an appropriate dilution factor, and compared against an 11 point 
standard calibration curve (1-10,000 nM) prepared in DMSO and spiked into blank plasma. 100µl 
acetonitrile was added with the internal standard, followed by centrifugation, and supernatants 
were then diluted 1:7 in water and analysed via UPLC-MS/MS using a Xevo TQ-S mass spectrometer 
(Waters) and the system and optimization parameters listed (Supplementary Table 1, 2) . 
Ex vivo studies 
CDX tumors were dissociated as previously described (13) and cells were grown in HITES medium 
supplemented with 5 M Y-27632 (Selleckchem) and 2.5% FBS. CDX-derived cells were seeded into 
96 well plates, incubated for 48 hours, and treated with increasing concentrations of the 
compound(s) of interest. Seven days after treatment, cell viability was assessed via Cell-Titer Glo 3D 
assay (Promega). Single dose response curves were computed with the open source CRUK software 
Combenefit (14). Combinatorial activity was assessed using the Loewe additivity model (15) and 
computed using the R package synergyfinder (16).  For radiosensitization assays, cells were 
irradiated with indicated doses using a Gulmay Bipolar 320kV X-ray source. After irradiation cells 
were plated into fresh media and viability was measured after five days. 
Rad51 focus assay 
CDX-derived cells were irradiated with 10Gy and incubated for the indicated times. After incubation, 
cells were cytospun at a concentration of 150,000 cells per slides , fixed in 4% PFA for 20 min at 
room temperature, permeabilized with 0.2% triton X-100 (Sigma), and washed with 10% FBS 0.2% 
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Tween20 in PBS. Samples were then blocked with avidin/biotin blocking solution (VECTOR 
laboratories, SP-2001) and 10% goat serum (Dako). Sections were then incubated with primary 
antibodies (Supplementary Table 3) overnight at 4oC overnight, washed, and incubated with 
secondary antibodies for 1 hour at room temperature. Slides were mounted in ProLong DAPI (Life 
Technologies) and left dry in the dark. Images were acquired with a Leica gated Stimulated Emission 
Depletion microscope and cells were scored as HR-proficient if there were ≥5 foci per nucleus. 
Immunohistochemistry 
4µm formalin fixed paraffin embedded tumor sections were stained for the indicated antigens using 
the BondMax autostainer and Bond polymer refine detection system (Leica Biosystems), Venatana 
Discovery Ultra, or I6000 BioGenex autostainer and Dako EnVision system HRP (Dako)  
(Supplementary Table 3). For these antigens, digital images of whole tissue sections were acquired 
using a Leica SCN400 histology scanner (Leica Microsystems). Images were analysed using Definiens 
Developer XD and the Tissue Studio Portal version 4.4 (Definiens AG). 
Immunoblot analyses 
Flash frozen CDX tumors were homogenized in Fastprep tubes with matrix A using a TissueLyser LT 
(Qiagen) in ice cold lysis buffer (10mM HEPES pH 7.1, 50mM NaCl, 0.3M sucrose, 0.1mM EDTA, 0.5% 
Triton X-100, 1mM DTT; or 20mM Tris, 137mM NaCl, 10% Glycerol, 50mM sodium fluoride, 1mM 
activated sodium orthovanadate , 1% SDS, 1% NP40 substitute) in the presence of Protease Inhibitor 
Cocktail and Phosphatase Inhibitor Cocktail I and III (Sigma-Aldrich). Protein concentration was 
determined by BCA protein assay reagent kit (Thermo Scientific). Protein extracts were resuspended 
in NuPAGE LDS sample buffer 4x (Invitrogen) and 10x NuPAGE sample reducing agent (Invitrogen). 
Total protein was resolved on a NuPAGE 4-12% Bis-Tris 1.0 mm gel (Invitrogen). After transfer onto 
PVDF or nitrocellulose membranes, blots were incubated with the appropriate primary antibody 
(Supplementary Table 3) and the corresponding horseradish peroxidase-coupled secondary IgG. 
Detection was obtained with the Supersignal West Dura extended duration substrate 
(ThermoFisher) on a ChemiGenius Imaging System (Syngene) or film. 
PAR ELISA 
Flash frozen CDX tumor tissue was homogenized for 3x30 seconds at speed 6.0 in Fastprep tubes 
with matrix A using ice cold lysis buffer (20mM Tris, 137mM NaCl, 10% Glycerol, 50mM sodium, 
1mM activated sodium orthovanadate, 1% SDS, 1% NP40 substitute in the presence of protease 
inhibitor cocktail (Roche) and phosphatase inhibitor cocktails 2 & 3 (Sigma-Aldrich). Lysates were 
sonicated, incubated on ice for 30 minutes, centrifuged, and supernatants were boiled for five 
minutes. They were then cooled on ice for one minute, centrifuged, and protein concentration was 
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estimated using a Pierce BCA assay. 2µg lysate was used to quantify total PAR levels according to 
manufacturer’s recommendations (Trevigen). Samples were quantified on a Tecan Safire II 
microplate reader (Tecan) and absolute values were determined via interpolation from a standard 
curve. 
RNAseq 
Total RNA was extracted from three independent RNAlater (Qiagen) -treated tumors from each 
model with RNeasy mini kits (Qiagen) and quantified by Qubit (Thermo Fisher). RNA with an RNA 
integrity number (RIN) > 8 (Agilent 2100 Bioanalyzer) was used to generate libraries with SureSelect 
poly A samples (Agilent) and sequenced on the NextSeq 500 using 75 bp paired end reads. RNASeq 
data was aligned to Human GRCh38 and Mouse GRCm38 assembly using Mapsplice (version 2.1.6).  
Xenograft data was filtered via a novel algorithm to distinguish human and mouse reads (17). The 
filtered reads are then used to generate counts data using Rsubread package (version 1.16.1) with 
Ensembl 77 GTF file in R. The counts were converted into RPKM values using edgeR (version 3.10.5). 
Whole exome sequencing (WES) 
Genomic DNA was extracted from a representative flash frozen CDX tumor from each model with 
DNeasy Blood and Tissue kits (Qiagen) and quantified by Qubit.  150 base pair paired-end reads were 
obtained from samples assessed on a NextSeq 500 High run (Illumina).  The WES data was aligned to 
Human GRCh37 and Mouse GRCm37 assembly with bwa-mem (version 0.7.12). Deduplication, 
realignment and recalibration were performed on the aligned data using Picard (version 1.96) and 
GATK tools (version 3.3), as stated in the GATK best practices. The reads aligning to mouse genome 
were removed using an in-house developed algorithm (17). Somatic mutation calling was done on 
the filtered reads using Mutect (version 1.1.7) and the mutation calls were annotated using Ensembl 
Variant Effect Predictor. 
Statistics 
All statistical analyses were performed on Prism v7.04 (GraphPad) using one-way ANOVA or 
Student’s t-test for multiple or single pairwise comparisons, respectively.  Single and double asterisks 
denote p < 0.05 and p < 0.005, respectively.  The absence of an asterisk means that there is no 
statistically significant difference between groups. 
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Results 
To examine the efficacy of olaparib and AZD1775 in SCLC, we first treated two previously 
characterised CDX models representative of chemosensitive and chemorefractory patient donors (3).  
The chemosensitive CDX3 and chemoresistant CDX4 models were generated from baseline blood 
samples taken from a patient that lived for 9.7 months and 0.9 months, respectively, following 
treatment with platinum-based therapies.  Treatment of mice bearing CDX3 tumors with either 
olaparib or AZD1775 monotherapy led to complete or modest regression, with tumors rapidly 
recurring after treatments ended (Fig. 1, Supplementary Fig. 1a). Remarkably, combination therapy 
in CDX3 promoted complete and durable regressions with 5/7 mice remaining tumor-free for over 1 
year.  Conversely, CDX4, a model completely resistant to cisplatin/etoposide, showed no response to 
olaparib whereas treatment with either AZD1775 monotherapy or the combination led to disease 
stabilization during the treatment period (Fig. 1, Supplementary Fig. 1b). 
Topotecan, a DNA damaging agent that is the only approved second-line therapy for SCLC, was more 
effective than cisplatin/etoposide against CDX4, eliciting a median 66% tumor regression 
(Supplementary Fig. 1e). Furthermore combination of topotecan with AZD1775 yielded impressive 
tumor regression in this model, with median 83% tumor regression. These data indicate that 
AZD1775 can cooperate with an effective DNA damaging agent even in a platinum-resistant model.    
The majority of SCLC patients present with chemosensitive disease followed by rapid acquisition of 
chemoresistance and disease progression. To examine the efficacy of the olaparib/AZD1775 
combination in patients with acquired chemoresistance, we utilised a pair of CDX models, CDX8 and 
CDX8p, which were derived from blood samples from the same patient taken at baseline and upon 
disease progression after platinum treatment (Supplementary Fig. 2a). Treatment of CDX8 tumors 
with cisplatin/etoposide induced a partial response (median 47% regression) and rapid relapse 
(median tumor growth delay (TGD)=1.9), whereas mice bearing CDX8p received little benefit from 
cisplatin/etoposide treatment (median 15% growth and TGD=1.3), consistent with the outcome of 
chemotherapy in the donor patient (Fig. 1, Supplementary Fig. 2b, c). When these models were 
treated with olaparib or AZD1775, CDX8 exhibited relatively stable disease during the treatment 
period, whereas CDX8p tumors grew at the same rate as the vehicle control cohort (Fig. 1, 
Supplementary Fig. 1c, d). Similar to that seen in CDX3, the combination exhibited synergistic 
activity against CDX8 with many complete regressions. Although CDX8 tumors recurred more quickly 
than CDX3 tumors (Fig. 1b), olaparib/AZD1775 yielded a more durable response than 
cisplatin/etoposide (median TGD=1.9) (Fig. 1). Consistent with reports of reduced olaparib efficacy 
Research. 
on August 17, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 25, 2018; DOI: 10.1158/1078-0432.CCR-17-2805 
 
 
11 
 
against platinum-resistant ovarian cancer (18), treatment with olaparib alone or in combination with 
AZD1775 achieved only tumor growth delay rather than regression in CDX8p (Fig. 1, Supplementary 
Fig. 1d). Taken together these results indicate that although the efficacy of olaparib/AZD1775 was 
model dependent, the activity of the combination is consistently superior to that achieved with 
conventional cisplatin and etoposide in chemosensitive models.  Furthermore, the combination of 
AZD1775 and an active DNA damaging agent has activity in a chemoresistant model.  
As platinum-based regimens are initially quite effective in treating SCLC, it is unlikely that 
olaparib/AZD1775 or any other new agent will be used clinically in treatment-naïve patients. We 
therefore sought to examine the efficacy of olaparib/AZD1775 in a second-line setting following 
initial treatment with cisplatin/etoposide. Toward this end, we treated mice bearing CDX3 tumors 
with a single cycle of cisplatin/etoposide to induce an initial tumor response. After a three week 
drug holiday during which tumors began to re-grow, mice were randomized to receive vehicle, 
olaparib, AZD1775, or the combination. In this setting, only 1/12 combination-treated mice 
remained tumor free and the median time to initial tumor volume was 101 days following 
completion of dosing (Supplementary Fig. 3), suggesting that this combination is still active after 
initial treatment with cisplatin/etoposide but may prove most beneficial as a first-line option if the 
proper patient cohort could be identified. 
In vivo pharmacology experiments are both time consuming and expensive, so we sought to use an 
in vitro platform to expedite drug screening as previously reported for colorectal and breast cancers 
(19,20).  Using an ex vivo SCLC CDX culture system that faithfully recapitulates in vivo drug response 
in CDX models (21), we investigated the in vitro efficacy of olaparib, AZD1775, and the combination.  
Both monotherapies as well as the combination correlated with in vivo response, with evidence of 
synergy in CDX3 and CDX8, but not CDX4 or CDX8p (Fig. 2a-d, Supplementary Fig. 4).  We therefore 
decided to screen additional CDX models with varying sensitivity to platinum, derived from baseline 
and relapse patients (Table 1). Examination of ex vivo cultures derived from CDX2, CDX3p, CDX10, 
CDX14p, CDX15p, and CDX15p2 revealed a range of sensitivity to cisplatin and olaparib 
monotherapies, whereas most models were relatively sensitive to AZD1775 with submicromolar 
GI50’s. Similarly, the majority of models were sensitive to olaparib/AZD1775, although CDX4 and 
CDX8p were among the most resistant in vitro (Fig. 2e). These results from a broader panel of CDX 
models tested in vitro, support our findings that olaparib/AZD1775 is an effective combination and 
may represent a promising treatment for SCLC. 
It has previously been reported that olaparib is a CYP3A substrate and that AZD1775 is a CYP3A4 
inhibitor (22), therefore it was possible that the combination effect seen in some CDX models could 
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be attributed to a drug-drug interaction in which elevated levels of olaparib result from inhibition of 
CYP3A by AZD1775. To examine this possibility we administered 50 mg kg-1 olaparib (olaparib low) 
both alone and in combination with AZD1775 as previously described, or 100 mg kg-1 olaparib alone 
(olaparib high) to CDX3-bearing mice. Increasing the dose of olaparib to 100 mg kg-1 had no 
significant effect on anti-tumor efficacy against CDX3 (Fig. 3a), and pharmacokinetic analysis of 
olaparib and AZD1775 indicates that mice dosed with the combination are not exposed to plasma 
drug concentrations significantly different to mice receiving monotherapies (Fig. 3b, c). Therefore 
the efficacy of the olaparib/AZD1775 combination is unlikely to be due to altered olaparib exposure. 
To examine the molecular mechanism of olaparib and AZD1775 efficacy, we treated parallel cohorts 
of mice with a single dose of drug and examined intra-tumor signal transduction pathways and 
cellular behaviour. Wee1 kinase regulates G2/M progression by directly phosphorylating and 
inhibiting the cell cycle kinase CDK1 and this has been used both preclinically and clinically as a 
pharmacodynamic biomarker of Wee1 inhibition (9).  Consistent with Wee1 inhibition, phospho-
CDK1 levels were reduced and the number of mitotic cells was increased in cohorts treated with 
AZD1775 either alone or in combination with olaparib (Fig. 4a, c; Supplementary Fig. 5). Similarly, 
global PAR levels were decreased in all cohorts treated with olaparib (Fig. 4b). Together these data 
indicate that the different levels of efficacy in different CDX models cannot be attributed to 
differential target inhibition. Examination of cleaved caspase 3 levels revealed that increased levels 
of apoptosis correlated with anti-tumor efficacy (Fig. 4d; Supplementary Fig. 5). Since treatment 
with both olaparib and AZD1775 promoted increased DNA damage, we investigated several 
pathways associated with the DNA damage response. 
CHK1 phosphorylation by ATR is induced by the formation of regions of single strand DNA (ssDNA) 
either resulting from the processing of DNA double strand breaks (DSBs) or stalled DNA polymerase 
during DNA synthesis due to replicative stress (9). The extended ssDNA is coated by replication 
protein A (RPA) which binds ATR and associated proteins that initiate the replication stress response 
that includes the phosphorylation and activation of CHK1. The inability to resolve replication stress-
induced fork stalling can lead to replication fork collapse, the generation of a single-ended DSBs, and 
ATM-induced H2AX phosphorylation.  Consistent with previous reports, treatment with AZD1775 
promoted potent CHK1 phosphorylation, indicative of Wee1 inhibition increasing replication stress 
(23). However, this effect was similar in all models examined and did not correlate with efficacy (Fig. 
4e, Supplementary Fig. 1). Conversely, induction of γH2AX more closely correlated with in vivo 
efficacy and highest levels were seen when AZD1775 was combined with olaparib in CDX3 and CDX8, 
the two most sensitive models (Fig. 4f, Supplementary Fig. 1). 
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The BRCA1 and BRCA2 gene products are key DDR proteins that play different but pivotal roles in 
DNA DSB repair (DSBR). Both proteins have been shown to play key roles in the replication stress 
response as well through replication fork stabilisation and restart, and deficiencies in either lead to 
PARP inhibitor sensitivity (24).  Given this association, we were interested to know the DSBR status 
in our CDX models. BRCA and broader HRR deficiencies have been identified via a variety of 
mechanisms including transcriptional or mutational impairment of genes that regulate homologous 
recombination repair, the accumulation of ’genomic scars‘, or functional assays such as DNA 
damage-induced Rad51 focus formation (24). Analysis of RNAseq data on CDX models did not reveal 
an obvious HRR mutation signature that correlated with sensitivity, nor did whole exome sequencing 
reveal an elevated mutation burden associated with impaired DSBR (Supplementary Fig. 6a, b).  
Despite the absence of an HRR mutation signature, CDX3 is exquisitely radiosensitive compared to 
CDX4, indicating that CDX3 is potentially deficient in DSBR (Fig. 5a). Functional assessment of HRR 
status via examination of ionizing radiation-induced Rad51 focus formation revealed that CDX3 
displayed signs of HRR deficiency, suggesting this model may harbour a mutation in a gene that 
mediates HRR (Fig. 5b). PALB2 is a BRCA2-associated DDR protein required for effective HRR (9). 
Whole exome sequencing of CDX3 revealed a somatic mutation in PALB2 that resulted in a stop-gain 
at E178 leading to premature truncation of the protein (Fig. 5c, d).  Analysis of RNAseq data 
indicates that all PALB2 reads harbour this mutation, suggesting a complete loss of the wild type 
allele (Supplementary Fig. 6c).  Therefore it is highly likely that the exquisite sensitivity of CDX3 to 
both platinum and olaparib can be attributed to the PALB2 mutation. 
Several additional mechanisms of acquired resistance to olaparib have been reported, including 
activation of PI3K or Met signalling (25,26), decreased expression of PARP1 or SLFN11 (27-30), and 
restoration of DNA end resection (31). We did not find any consistent differences in MET or PI3K 
signaling, suggesting that activation of these kinases is not a recurrent mechanism of olaparib 
resistance in SCLC (Supplementary Fig. 7a).  PARP-trapping is now recognized as the primary 
mechanism of PARP inhibitor-mediated cytotoxicity, and loss of expression of PARP1 is thus 
associated with resistance. However, expression analysis did not reveal any alteration in PARP1 
expression in either CDX4 or CDX8p (Supplementary Fig. 7b). SLFN11 binds to RPA, and it has been 
postulated that high SLFN11 levels inhibit homologous recombination repair by promoting the 
destabilization of the interaction between RPA and ssDNA (32). Although CDX4, the most olaparib-
resistant model, exhibits the lowest SLFN11 levels, this correlation does not extend to CDX8p 
(Supplementary Fig. 7c). End resection is the process of creating stretches of ssDNA necessary for 
Rad51-induced strand invasion and subsequent repair via homologous recombination. In the context 
of functionally relevant BRCA1 mutations, decreased expression of the non-homologous end joining 
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(NHEJ) proteins 53BP1 and Rev7 have been reported to result in restoration of end resection 
activation of HRR and consequently resistance to PARP inhibitors (33,34). However, neither CDX4 
nor CDX8p have decreased expression of either protein compared to CDX3 or CDX8 (Supplementary 
Fig. 7c).  Although CDX8 harbours a C342F mutation in FANCD2, a key player in the Fanconi anaemia 
pathway that includes BRCA, this mutation is still present in CDX8p and, in the absence of any 
TP53BP1-associated mutation, is unlikely to explain the acquired chemoresistance manifest in 
CDX8p.  Neither whole exome sequencing nor RNAseq has identified likely candidates of resistance, 
and we are actively pursuing additional strategies to discover the mechanism of acquired drug 
resistance in CDX8p. 
One proposed predictive biomarker of AZD1775 sensitivity is the absence of a G1/S checkpoint (35).  
It has been hypothesized that cells with a compromised G1/S checkpoint are more dependent on the 
G2/M checkpoint, and therefore sensitive to Wee1 inhibition. Given the role for p53 in regulating 
the G1/S checkpoint, multiple studies have investigated whether p53 mutations are stand-alone 
biomarkers for AZD1775 sensitivity (10,36). Although all SCLC models tested harbour deleterious 
mutations in TP53, chemoresistant models tend to retain relatively high levels of the cyclin 
dependent kinase inhibitor p21CIP1, a primary mediator of p53-dependent cell cycle arrest (Fig. 6a, 
b).  Although treatment does not induce expression of p21CIP1 (Supplementary Fig. 8), p53-
independent activation of p21CIP1 may partially mediate resistance to AZD1775 by maintaining the 
G1/S checkpoint in p53-deficient cells. The majority of SCLC cells also possess mutations in RB1, 
which regulates entry into S-phase.  We therefore investigated whether RB1 status correlates with 
AZD1775 sensitivity.  Whole exome sequencing and RNAseq revealed RB1 mutations in CDX3 (splice 
mutation at 5’ of exon 17, c.1499-1G>T), CDX4 (87bp deletion in exon 1 and intron 1, 
c.99_137+48del), and CDX8/8p (G509*), and none of the models used in this study express pRB as 
determined by western blotting (Fig. 6a). Moreover, there is no consistent correlation between 
cyclin/CDK expression and sensitivity to AZD1775.  This does not rule out the potential importance of 
deregulation of the G1/S checkpoint but does suggest that, at least in SCLC, regulators of G1/S CDKs 
alone do not appear to be predictive biomarkers of AZD1775 sensitivity. 
Low expression of PKMYT1, a cell cycle kinase that is functionally redundant to Wee1, can 
predispose cancer cells to AZD1775 sensitivity by lowering the threshold of kinase inhibition (37).  
However, while the most sensitive models do have the lowest levels of PKMYT1 RNA, there is no 
correlation between PKMYT1 levels and CDK1 phosphorylation, suggesting this is unlikely to be a 
major factor governing AZD1775 sensitivity (Fig. 4a, Supplementary Fig. 9a). 
Research. 
on August 17, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 25, 2018; DOI: 10.1158/1078-0432.CCR-17-2805 
 
 
15 
 
Several studies have reported a link between sensitivity to Wee1 inhibition and replication stress 
(38).  Replication stress is a general term used to describe situations that result in stalled replication 
fork progression and the generation of extended regions of ssDNA (39). Replication stress can be 
induced by overexpression of oncogenes such as MYC family members or cyclin E, which can both 
deplete nucleotides as a result of deregulated origin firing and promote collisions between the 
transcription and replication machinery (40).  Wee1 plays a key role in the replication stress 
response by regulating CDK2 and markers of replication stress such as pRPA have been shown to 
increase upon treatment with a Wee1 inhibitor (41). Immunoblot analysis revealed that CDX3, the 
model that is most sensitive to AZD1775, expressed high levels of L-Myc, cyclin E1, and phospho-RPA 
(Fig. 6c).  Consistent with a recent report that tumors deficient for the histone methyltransferase 
SETD2 and ribonucleotide reductase subunit RRM2 are synthetic lethal with AZD1775 treatment 
(42), CDX3 expressed approximately half as much SETD2 and RRM2 compared to CDX4 and 
treatment with AZD1775 either alone or in combination with olaparib lead to modest reductions in 
RRM2 levels (Supplementary Fig. 9a, b)   Moreover, AZD1775 treatment further increased pRPA 
levels in CDX3 but not CDX4 (Fig. 6d).  Together these data suggest that both baseline and 
treatment-induced replication stress may predict sensitivity to AZD1775. 
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Discussion 
SCLC is a cancer of high unmet need and, despite promising preclinical (43) and early clinical results 
(44) utilizing a DLL3-targeted antibody-drug conjugate, there have been no improvements in 
systemic therapy in three decades. Whilst approximately 100 SCLC trials have been registered on 
clinicaltrials.gov since 2007, strikingly few involved more than 100 patients, many are single arm 
studies, and correlative biomarker assessment is rarely obtained largely due to the difficulties in 
obtaining serial tumor biopsies. The statement in the US Recalcitrant Cancer Act 2012 that “more 
knowledge of the biology at different phases of SCLC is needed” can partially be attributed to the 
lack of relevant models.  Indeed, the recently reported “patient-derived tumor encyclopedia” that 
contains over 1000 PDX does not contain a single SCLC model (45) and 21/26 SCLC PDX that have 
been published were derived prior to treatment of the donor patient with chemotherapy (43,46,47).  
Our CDX models and notably those obtained both at baseline and at progression after chemotherapy 
and reported here for the first time, offer a new approach to study acquired treatment resistance 
and test novel therapies in both first and second line settings. Utilizing these patient-relevant models 
derived from liquid biopsy, we demonstrated here that the combination of olaparib and AZD1775 
exerted significant activity against a panel of SCLC CDX models that span the spectrum of responses 
to standard of care chemotherapy, with some demonstrating a profound and extended response to 
this novel combination.   
The PARP inhibitor olaparib is currently being investigated in clinical trials, however the genetic 
determinants of drug sensitivity remain incompletely defined. Our CDX models offer the opportunity 
to investigate both predictive biomarkers and mechanisms of drug resistance. We observed the 
most striking combination efficacy in models where both monotherapies had some effect. Olaparib 
was most efficacious against CDX3, a model that failed to express homologous recombination repair 
protein PALB2. Although damaging PALB2 mutations are reported to account for outlier responses to 
PARP inhibitors in other cancer types (48,49), targeted therapies that work in one cancer type do not 
necessarily work in another cancer type, even if the genetics are similar (e.g. vemurafenib in BRAF-
mutant melanoma vs colorectal cancer (50)). To our knowledge this is the first report correlating a 
PALB2 mutation to combined olaparib/wee1 inhibition in SCLC. Moreover, SCLC tumors are not 
typically associated with defects in homologous recombination repair, a known predictive biomarker 
for PARP inhibitor sensitivity, and our data suggest further research into this area is warranted.  
Multiple studies have shown that olaparib efficacy is significantly reduced against tumors pre-
treated with chemotherapy. We sought to address this by examining the efficacy of 
olaparib/AZD1775 against a model generated from a patient who progressed on a platinum-based 
Research. 
on August 17, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 25, 2018; DOI: 10.1158/1078-0432.CCR-17-2805 
 
 
17 
 
therapy. Consistent with patient progression, CDX8p was resistant to treatment with 
platinum/etoposide. Although CDX8p was also relatively insensitive to olaparib/AZD1775, this 
combination elicited a more durable response than platinum/etoposide. Similarly, pre-treatment of 
CDX3 with platinum/etoposide blunted the response of chemonaive CDX3 to olaparib/AZD1775. 
Given the deep, though short lived response to patient standard of care platinum-based 
chemotherapy, it may be challenging to administer an olaparib/AZD1775 combination to treatment-
naive SCLC patients.  However, consideration should be given to minimising the number of 
chemotherapy cycles given to debulk the disease prior to testing this novel combination. 
The exquisite sensitivity of CDX3 to combination therapy is likely due to the fact that both olaparib 
and AZD1775 exhibited single agent efficacy against this model. AZD1775 can both compromise the 
ability to restrain mitotic commitment in response to DNA damage and promote catastrophic DNA 
damage in G1/S via inappropriate activation of the MUS81-SLX4 nuclease (51).  Thus, combinatorial 
activity of olaparib/AZD1775 may stem from AZD1775-induced inappropriate cleavage of stalled 
replication forks stemming from PARP trapping.  However, our understanding of the biology of 
inappropriate induction of these pathways in S phase remains in its infancy and a detailed 
mechanistic understanding of what role PARP may play in this process remains beyond the scope of 
this study. 
In addition to affecting sensitivity to olaparib, the PALB2 mutation could potentially explain the 
response of CDX3 to AZD1775. BRCA2 and PALB2 function has been linked to replication fork 
stabilization/restart as part of the replication stress response. CDX3, the model that is most sensitive 
to AZD1775 single treatment, already has significantly elevated levels of replicative stress as 
indicated by elevated levels of L-Myc, cyclin E, and pRPA compared to the lesser responsive models. 
Moreover, we have demonstrated that following AZD1775 treatment there is a further increase in 
pRPA. Phosphorylated RPA can recruit PALB2 and BRCA2 to the stalled fork, and PALB2 loss has been 
associated with defects in the recovery of the stalled fork and therefore increased DNA damage (52). 
Additionally, BRCA2 and PALB2 are key regulators of the G2/M cell cycle checkpoint upon DNA 
damage (53). Therefore, the absence of PALB2 in combination with the inhibition of Wee1 could 
increase premature mitotic entry and therefore genomic instability in CDX3 cells. Together, these 
data suggest the efficacy of the olaparib/AZD1775 combination is likely to involve both an increase 
in replication stress response in S-phase as well as carryover of S-phase induced damage into 
mitosis. 
Combination trials using PARP inhibitors are already in early phase development, including a second 
line study comparing temozolomide and veliparib with temozolomide and placebo where the 
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combination reported increased response rates but no significant difference in 4 month progression 
free survival (54). The ongoing Phase 1/2 trial of olaparib and temozolomide in patients progressing 
after chemotherapy also reported a 46% response rate for the combination compared to 14% for 
temozolomide alone (55). Olaparib/AZD1775 has demonstrated preclinical activity against AML(56), 
and a phase I clinical trial utilizing olaparib and AZD1775 has been initiated in patients with 
refractory solid tumors (https://ClinicalTrials.gov/show/NCT02511795), including SCLC, and an 
extended cohort in SCLC is planned. 
Conversion of improved clinical response rates to lengthened progression free and overall survival 
will likely require development of robust predictive biomarkers. Our preclinical CDX data suggest 
that predicting the depth and duration of responses to olaparib and AZD1775 in SCLC patients is 
unlikely to be straightforward; the speed with which acquired chemotherapy resistance occurs, the 
genomic instability and heterogeneity of this devastating disease all point to the need for 
development of broad biomarker panels for the optimal use of this combination therapy, where 
different patients’ tumors may acquire resistance via different and multiple molecular mechanisms. 
Further characterization of the DNA damage response status across a wide range of SCLC tumors, as 
well as functional validation of potential biomarkers is ongoing.  Our results raise the possibility that 
a subset of SCLC may have defects in DNA damage response pathways that could be exploited by the 
combination of PARP and Wee1 inhibitors.  Moreover, replication stress is often associated with 
oncogene overexpression and MYC family members, which are known to be amplified in 
approximately 20% SCLC and the role of MYC as a predictive biomarker of response to olaparib and 
AZD1775 can now be studied further in our burgeoning panel of 45 CDX models  (57-59). The CDX3 
cellular context represents a ‘super responder’ to the olaparib/AZD1775 combination and has 
revealed important molecular insights that we can now take forward in an assessment in the larger 
CDX panel. 
Surgical specimens and archival biopsies are unlikely to reflect the disease after 1st or 2nd line 
treatments. We previously reported the prevalence of CTCs in SCLC (60), their prognostic 
significance and their potential as a readily obtained and repeatable source of pharmacodynamic 
and predictive biomarkers. Moreover, mutations in a panel of genes associated with DNA damage 
response measured in circulating tumor DNA may also assist patient selection. These liquid biopsy 
approaches should now be fully exploited in upcoming trials of novel therapies in SCLC where 
promising data in patient relevant preclinical models is forthcoming. 
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Table 1 
Model Pt treatment Tumor 
response1 
Chemosensitivity Pt survival 
(days)1 
CellSearch 
count2 
2 carbo/etop PR refractory 108 1625 
3 carbo/etop PR sensitive 295 507 
3p  relapse  295 463 
4 carboplatin PD refractory 27 1375 
8 carboplatin PR refractory 181 388 
8p  relapse  181 1796 
10 carbo/etop PR sensitive 317 160 
14p  relapse  227 362 
15p  relapse  556 361 
15p2  relapse  556 165 
1 Survival is defined as the time from diagnosis until death 
2 The number of EpCAM+/CK+ CTC’s in a parallel 7.5ml blood sample taken from the same 
patient bleed that yielded the corresponding CDX. 
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Figure Legends 
Figure 1. Combination treatment with olaparib/AZD1775 is superior to cisplatin/etoposide.  a) The 
cohort average best response (+/- sd) is shown for cisplatin/etoposide (white), AZD1775 (red), 
olaparib (green), or the AZD1775/olaparib (blue). b) The cohort average benefit (+/- sd) of each 
treatment over vehicle is shown for each treatment.  Cohort sizes are > 7. * p<0.05; ** p<0.005 vs. 
cisplatin/etoposide treatment. 
Figure 2. AZD1775 and olaparib are synergistic in vitro. CDX3 (a), CDX4 (b), CDX8 (c), or CDX8p (d) ex 
vivo cultures were treated with AZD1775 and olaparib for 1 week and relative cell viability was 
assessed.  One representative experiment of at least three is shown. For the combinatorial index, 
red is indicative of synergy and green is indicative of antagonism between drugs.  e) GI50 values for 
various CDX ex vivo cultures treated with cisplatin, etoposide, AZD1775, or olaparib are shown after 
1 week of drug treatment.  For the combination we have shown the GI50 values for olaparib at 150 
nM AZD1775.  
 
Figure 3. Pharmacokinetic analyses.  a) Mice were treated with 100 mg kg-1 (dark green) or 50 mg kg-
1 (dashed green) olaparib, or with a combination of low dose olaparib and AZD1775 (blue) for 21 
days and tumor volumes were measured biweekly.  Individual relative tumor volumes are depicted.  
Tumor lysates from cohorts of mice bearing different CDX models treated with AZD1775 (red), 
olaparib (green), or the combination (blue) were analysed and quantified for AZD1775 (b) or olaparib 
(c) at 2 hours after a single dose.    Dashed lines represent the reliable limits of detection. Cohorts of 
> 4 tumors were used. 
 
Figure 4. Pharmacodynamic analyses.  Tumor lysates from cohorts of mice bearing different CDX 
models treated with a single dose of vehicle (white), AZD1775 (red), olaparib (green), or the 
combination (blue) were analysed and quantified.  Cohorts of > 4 tumors were used. a) pCDK1 levels 
were measured by immunoblotting 2 hours after a single dose and normalised to both total CDK1 
and vinculin in each sample. b) Total PAR levels were measured by ELISA 2 hours after a single dose. 
The dashed line indicates the limit of detection (2pg/ml). Proof of concept and proof of mechanism 
biomarkers were measured by quantitative immunohistochemistry for pHH3 at 2 hours (c), CC3 at 24 
hours (d), pCHK1 at 2 hours (e), and γH2AX at 24 hours (f) after dosing. * p<0.05, **p<0.005 
 
Figure 5. Deficient double strand break repair in CDX3.  a) CDX3, CDX4, CDX8, and CDX8p ex vivo 
cultures were irradiated at indicated doses in triplicate and relative cell viability was assessed 5 days 
later.  One of three representative experiments is shown.  b) At indicated times following irradiation, 
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CDX3 and CDX4 cultures were assessed for Rad51 focus formation. Geminin and DAPI staining was 
used to identify cells in G2, and these results were quantified by a semi-automated computer 
algorithm.  The dashed line indicates a threshold above which cells are considered positive for 
damage-induced focus formation. **p<0.005 c) Sanger sequencing identified the E178* PALB2 
mutation in CDX3, but not CDX4. d) Schematic of PALB2 with protein-protein interaction domains 
shown in grey and the E178* mutation shown in red. 
 
Figure 6. Sensitivity to AZD1775 correlates with markers of replication stress. a) Immunoblot analysis 
of duplicate tumor lysates for indicated proteins. The p53 mutation associated with a given model is 
indicated.  The positive control for RB is the H1694 cell line. b) Representative images and 
quantification of p21CIP1 IHC from CDX3, CDX4, CDX8, and CDX8p.  p21CIP1 levels are plotted against 
tumor regression values for each model.  c) Immunoblot analysis of duplicate tumor lysates for 
indicated proteins. Corresponding average RPKM values for L-Myc and C-Myc in each model are 
indicated below immunoblots.  N-Myc expression was not investigated, however RPKM values below 
5 suggest it is not expressed in the models investigated.   d) Immunoblot analysis of duplicate lysates 
from CDX3 and CDX4 tumors treated with vehicle or AZD1775 for 24 hours.  The positive control for 
L-Myc is the H1694 cell line. 
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